Tuesday, November 24, 2009, 8:44pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

GenVec Inc. (GNVC)

At 4:59AM SGT: 0.935 USD   0.00 (0.00%)  
 MORE ON GNVC 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 GenVec, Inc. (NGM:GNVC) Delayed quote dataEdit
Last Trade:0.935 USD
Trade Time:4:59AM SGT
Change: 0.00 (0.00%)
Prev Close:0.935
Open:N/A
Bid:0.89 x 500
Ask:1.06 x 200
1y Target Est:2.00
Day's Range:N/A - N/A
52wk Range:0.30 - 1.17
Volume:0
Avg Vol (3m):1,909,470
Market Cap:99.42M
P/E (ttm):N/A
EPS (ttm):-0.221
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add GNVC to Portfolio   Download Data

 HEADLINES 
•[$$] Biotech Stock Mailbag: Cardium Therapeutics
at RealMoney by TheStreet.com (Fri, Nov 13)
•GENVEC INC Financials
EDGAR Online Financials (Wed, Nov 11)
•New Star Analyst Rankings for GenVec, Inc.
StarMine (Sun, Nov 8)
•GENVEC INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Sat, Nov 7)
•GenVec, Inc. Earnings Call scheduled for 10:00 am ET today
CCBN (Fri, Nov 6)
•GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Fri, Nov 6)
•GenVec Reports Third Quarter 2009 Financial Results
PR Newswire (Fri, Nov 6)
•GenVec signs $22 mln vaccine contract, shares up
at Reuters (Fri, Nov 6)
•GenVec Signs New Contract to Support HIV and Influenza Vaccine Development
PR Newswire (Thu, Nov 5)
•Q3 2009 GenVec, Inc. Earnings Release - After Market Close
CCBN (Thu, Nov 5)
More Headlines for GNVC...
 ANALYST 
EPS Est (next year) (Dec-09) :-0.17
EPS Est (in 2 years) (Dec-10) :-0.18
Avg Rec (current)*:2.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines in the United States. Its lead therapeutic product candidate, TNFerade biologic, is under Phase III trial for first-line treatment of inop...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices